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Angiotensin 11-stimulated expression of transforming growth factor
beta in renal proximal tubular cells: Attenuation after stable transfection
with the c-mas oncogene. Angiotensin II (Ang II) stimulates cellular
hypertrophy of cultured murine proximal tubular cells (MCT cells). This
Ang TI-mediated hypertrophy depends on the endogenous induction and
autocrine action of transforming growth factor-a (TGF-13). We have
previously demonstrated that permanent transfection of MCT cells with
the c-mas oncogene, whose protein product encodes a serpentine recep-
tor-like moiety coupled to G proteins without an hitherto identified ligand,
changes the hypertrophic actions of Ang II into a proliferative response
(AmJPhysiol263:F93l—F938, 1992). The present study demonstrated that
Ang II failed to stimulate induction of TGF-p1 protein in c-mas trans-
fected MCT cells under the control of SV 40 promoter/enhancer
(pSV2mas) as measured by mink cell bioassay and specific ELISA for
TGF-131. Moreover, in contrast to either wild-type MCT cells or to cells
permanently transfected with the SV 40 based expression plasmid only
(pSV2 cells), Ang II stimulated gene transcription and mRNA expression
of TGF-131 were decreased in c-mas transfected cells. Our findings
demonstrate that the Ang TI-induced proliferation of c-mas transfected
MCT cells most likely depends on failure of TGF-131 induction in these
cell. c-mas transfected cells are a useful tool to further investigate the
complex relationships between activation of second messengers subse-
quent to binding of Ang II to AT1-receptors and gene regulation like
transcription of TGF-131.
Angiotensin II (Ang II) has many diverse effects on renal
proximal tubular cells, including the activation of the luminal
Na41H exchanger and the stimulation of basolateral Na/
HC03 transport [1, 2]. In general, lower concentrations of Ang
II (10— 12 M) stimulate sodium, bicarbonate, and water reabsorp-
tion, whereas higher concentrations of the octapeptide (10 M)
inhibit transport processes [1, 2]. In addition, more recent exper-
iments suggest that Ang II also exerts metabolic effects on
proximal tubular cells like stimulation of gluconeogenesis and
ammonia production [3—5]. We and others have previously dem-
onstrated that Ang II is a potential growth factor for cultured
proximal tubular cells [6—101. The peptide inhibits proliferation,
but induces cellular hypertrophy as defined by increases in cell
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size, protein and RNA synthesis in a murine proximal tubular cell
line (MCT cells [6]) and LLC-PK1 cells [7—9]. This Ang Il-induced
hypertrophy is transduced by the AT1-receptor and depends on a
decrease in intracellular cAMP [7]. Moreover, we have previously
shown that Ang II stimulates expression of transforming growth
factor beta (TGF-/3) and that the induced hypertrophy depends
on this induction of TGF-/3 since neutralizing anti-TGF- anti-
bodies abolished the Ang Il-mediated cellular hypertrophy [10].
The c-mas oncogene, originally isolated from human epider-
moid carcinoma DNA by its tumorigenicity, codes for a GTP
binding protein with seven transmembrane spanning regions [11,
12]. Although originally thought to encode the Ang Il-receptor,
more recent studies indicate that the c-mas oncogene has only
20% homology with the recently cloned AT1-Ang II receptor
[13—15]. However, injection of c-mas mRNA into Xenopus oocytes
markedly increased the physiological response to Ang II without
changes in surface AT1-receptor density, suggesting that the
protein product of the c-mas oncogene interferes with the Ang
Il-associated signal transduction systems [13, 14, 16]. We have
recently observed that MCT cells stably transfected with the c-mas
oncogene exhibit a unique growth pattern after stimulation with
Ang II [17]. The peptide is mitogenic for these c-mas transfected
cells whereas it stimulates hypertrophy in parental wild-type MCT
cells or control cells transfected with the expression vector pSV2
without c-mas insert [17]. Since the Ang Il-mediated hypertro-
phogenic growth response in wild-type MCT cells depends on the
induction of TGF-/3, we tested in the present study whether
transfection with the c-mas oncogene may influence this expres-
sion of TGF-f3. Our results demonstrate that Ang II stimulates
transcription and synthesis of TGF-/3 in MCT cells as well as in
MCT cells transfected with the pSV2 expression plasmid, but not
in MCT cells transfected with pSV2mas.
Methods
Cell culture
MCT cells are an SV 40 transformed murine proximal tubular
cell line originally isolated from adult naive SJL mice. These cells
express many properties of proximal tubular cells and have been
characterized by various investigators [6, 18, 19]. Although MCT
cells were originally characterized in 1988 [18], for the present
study we used a sample frozen in 1990. These MCT cells still
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express Ang lI-receptors and stimulation with parathyroid hor-
mone induced an increase in intracellular cAMP (data not
shown). MCT cells have been permanently transfected with the
c-mas oncogene expressed under the control of SV 40 enhancer-
promoter elements in the plasmid pSV2mas [17]. This c-mas
expressing cell line was co-transfected with pSV2neo and selected
for stable transfectants with G418 (Gibco-BRL, Eggenstein, Ger-
many). An additional cell line was permanently transfected with
the pSV2 shuttle vector without the c-mas insert to serve as a
control [17]. Cells were routinely carried in Dulbecco's modified
Eagle's medium containing 450 mgldl glucose (DMEM) with 100
U/ml penicillin, 100 xg/ml streptomycin, and 10% heat-inacti-
vated fetal calf serum (FCS; Gibco). Cells were cultured at 37°C
in 5% CO2 and were passaged every 72 to 96 hours by light
trypsinization. Two-hundred xg/ml G418 was added to DMEM
for the normal maintenance of pSV2 and pSV2mas cell lines to
prevent spontaneous back mutations. However, no G418 was
added during the study phase of the experiments.
TGF-f3 assays
Active TGF-p was measured with the mink cell bioassay. The
CCL-64 lung epithelial cells are growth inhibited in the presence
of bioactive TGF-f3 [20]. CCL-64 cells were originally obtained
from the American Type Culture Collection (Rockville, MD,
USA) and were cultured at a concentration of i04 cells per well of
a 96-well culture plate (Greiner, Frickenhausen, Germany) in
DMEM with 10% FCS. Cells were made quiescent for 24 hours in
serum-free DMEM. CCL-64 cells were then incubated for an
additional period of 24 hours with 200 1.d per well of conditioned
medium (see below). To some wells containing conditioned
medium, 30 jxg/ml of a neutralizing monoclonal anti-TGF-1313
(Genzyme, Boston, MA, USA) was added to test for the specific-
ity of this bioassay [21]. The incorporation of [3H]thymidine into
CCL-64 cells was used as a measurement of proliferation [10].
CCL-64 cells were pulsed with 1 xCi/well [3Hthymidine (5
Ci/mmol; Amersham, Braunschweig, Germany) during the last six
hours of culture. At the end of the experiment, cells were washed
twice in PBS, trypsinated for 10 minutes at 37°C, and finally
collected on glass-fiber filters with an automatic cell harvester.
Radioactivity of dry filters was determined by liquid scintillation
spectroscopy. Conditioned medium was obtained from quiescent
(24 hr in serum-free DMEM) MCT cells, pSV2, and pSV2mas
transfected cells grown in 24-well plates (10 cells originally plated
per well) for 24 hours in either control medium (no Ang II), or in
the presence of 10—10 to 106 M of a single dose of Ang II (Sigma,
Deisenhofen, Germany). Conditioned medium was directly added
to CCL-64 cells without prior heat or acid activation. [3Hthymi-
dine incorporation into CCL-64 cells grown in conditioned me-
dium from MCT, pSV2, and pSV2mas cells in control medium (no
Ang II) was assigned a relative value of 100%. The bioassay was
independently repeated five times with two replicates from each
stimulation experiment.
In addition to the mink cell bioassay, total TGF-f31 was
measured in cell culture supernatants from MCT, pSV2 and
pSV2mas cells using a specific sandwich ELISA. For this assay, IO
cells were plated into each well of a 24-well culture plate, rested
in serum-free DMEM, and were treated for 24 hours with a single
dose of io to io M Ang II. At the end of the experiment, 200
jxl culture supernatant was removed from each well and incubated
with 20 xl I N HCI for 60 minutes to activate latent TGF-j31. After
neutralizing the supernatants with 1 N NaOH, samples were
measured with a commercial sandwich ELISA for TGF-p1 (Pre-
dicta, TGF-J31 kit, Genzyme) according to the manufacturer's
recommendations. A standard curve was constructed using serial
dilutions of ultrapure human TGF-p1 (Genzyme) as a standard.
Cells released from the 24-well plate by trypsination were counted
in a Fuchs-Rosenthal hemocytometer. Results are expressed as pg
TGF-p1/104 cells. Each sample was measured in duplicate from six
independent stimulation experiments.
Semiquantitative cDNA amplification
We initially used semiquantitative cDNA amplification as one
sensitive method to assess the level of TGF-p1 transcripts in the
pSV2 and pSV2mas cell lines [22—24]. Quiescent cells, grown for
24 hours in serum-free DMEM, were stimulated for another 24 to
48 hours with a single dose of 108 M Ang II. Cells were washed
twice in RNAse-free PBS and monolayers were directly lysed in 10
ml lysis buffer (4 M guanidinium isothiocyanate, 25 m sodium
citrate, pH 7; 0.5% sarcosyl, and 0.1 M 2-mercaptoethanol. Total
RNA was isolated by repeated phenol-chloroform extractions and
isopropanol precipitations. The quantity and purity of the prepa-
rations were assessed by measurement of absorption at 260 and
280 nm. eDNA was synthesized from 10 tg total RNA using 0.7
jxg of poly-d(T) primer (Pharmacia, Freiburg, Germany) with 500
U of Moloney murine leukemia virus reverse transcriptase
(Gibco-BRL) in a buffer containing 50 mrvi Tris-HC1 (pH 8.4), 75
mM KC1, 3 mrvi MgC12, 10 mM dithiothreitol, and 500 xM dNTPs
(Pharmacia). After first-strand eDNA synthesis, the reaction
mixes were precipitated with 7.5 M ammonium acetate and
isopropanol. The pellets were washed in 70% ethanol and resus-
pended in 50 x1 sterile water and absorption was measured at
260 nm. We used 500 ng eDNA for each amplification reaction
[23]. Polymerase chain reaction for the semiquantitative eval-
uation of TGF-f31 transcripts was normalized for the housekeep-
ing transcript GAPDH as previously described [23, 24]. A total of
150 ng of each of the following primers were used: mouse
TGF-/31 (sense, 5'CTCCCACTCCCGTGGCTITCTAG3'; anti-
sense, 5 'GTVrCCACATG11TGCTCCACACYTG3'), rat GAPDH
(sense, 5 'AATGCATCCTGCACCACCAA3'; antisense, 5 'GT-
AGCCATATT'CATn'GTCATA3'), and rat c-mas (sense, 5'CT-
GTCGGGCGGTCATCATCT3'; antisense, 5'CGCTTC'TTCCT-
TACIFGCTGCCC3'). The size of the TGF-/31 amplification product
is 471 bp, of the GAPDH product 512 bp, and the c-mas
amplification product is 345 bp. The correct identities of the
amplification products was previously confirmed by Southern
blotting and hybridization to endlabeled internal primers (data
not shown). In addition, to allow for a better quantification of
cDNAs which is independent of the exponential phase of the
amplification, polymerase chain reaction was also performed as
competitive reaction using an internal standard with known
concentrations having the same primer templates as the target
(PCR MIMIC kit for mouse TGF-/3; Clontech, Palo Alto, CA,
USA). Pilot experiments revealed that a concentration of iO M
was appropriate for the reactions. The size of the amplification
product of the internal standard is 390 bp. The GeneAMP kit
(Perkin Elmer Cetus, tJberlingen, Germany) was used for all
amplification reactions exactly as described previously [23] with
200 m of each dNTP and 2.5 U of Taq polymerase in amplifi-
cation buffer (20 mrvi Tris-HC1, pH 8.3; 25 mM KCI, 2.0 mrvt MgCl2,
and 0.05% Tween 20). A total of 40 cycles were performed with an
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annealing temperature of 58°C for 1.5 minutes, an extension step
at 72°C for 1.5 minutes, and a denaturation step at 92°C for one
minute. For competitive reactions with internal standards only 35
cycles were performed. Fifteen microliters of each reaction prod-
uct was then separated in a 1.9% agarose gel containing 0.5 jxg/ml
ethidium bromide to visualize the DNA. Gels were photographed
over ultraviolet light using Polaroid 55 negative film, and the
reaction products of the negative film were scanned by a laser
densitometer (GS 300, Hoefer Scientific Instruments, San Fran-
cisco, CA, USA). The area under the curves was determined by
Gaussian integration with the computer program GS 365W
(Hoefer). A normalization quotient between TGF-f31 and
GAPDH was calculated as described previously [23, 24]. In
addition a ratio between TGF-p product and internal TGF-13
standard was calculated. Controls (no Ang II) were assigned an
arbitrary value of one. A total of eight replicates (each represents
a separate cell stimulation experiment and amplification reaction)
was performed.
Northern hybridizations
To validate our cDNA amplification results, we performed
Northern blots. MCT, pSV2, and pSV,mas cells were stimulated
for 24 to 48 hours with a single dose of two different angiotensin
concentrations (10—8 and 106 M), and total RNA was isolated at
the end of each stimulation period as described above. Twenty
micrograms of total RNA were denatured in formamide-formal-
dehyde and electrophoresed through a 1.2% agarose gel contain-
ing 2.2 M formaldehyde. The RNA was subsequently vacuum
blotted to a nylon membrane (Zetabind, Cuno Laboratory Prod-
ucts, Meriden, CT, USA), and cross linked with UV short-wave.
All hybridization steps were carried out in a rotating drum in a
temperature-controlled oven. The membranes were prehybrid-
ized at 42°C for 24 hours in 5 X SSPE (20 X SSPE: 3 M NaC1, 0.2
M NaH2PO4, 0.02 M EDTA, pH 7.4), 5 X Denhardt's solution (50
X Denhardt's: 1% Ficoll, 1% polyvinylpyrrolidone, 1% bovine
serum albumin), 50% formamide, 0.1% sodium dodecyl sulfate
(SDS), and 150 xg/ml sonicated and denatured salmon sperm
DNA. cDNA inserts were separated from their vectors by agarose
electrophoresis and labeled with 5 jxCi [32P]deoxyadenosine
S'triphosphate (3,000 Ci/mmol; Amersham) using hexanuclear
primers. The probes used were an EcoRI fragment encoding the
murine TGF-31 gene [251, and a 2.0 kb cDNA insert of the
plasmid pMCI encoding the murine 18 5 RNA band. The labeled
fragments were separated from unincorporated nucleotides by
Sephadex G-50 chromatography. The membranes were hybrid-
ized with 106 cpm probe per ml hybridization buffer (same buffer
as used for prehybridizations) for 24 hours at 42°C. After hybrid-
izations, blots were washed twice in 2 x SSC (20 x SSC: 3 M NaCI,
0.3 M sodium citrate, pH 7.0), and 0.5% SDS at 65°C for 45
minutes. Autoradiography was performed with intensifying
screens at —70°C for two days (TGF-p1 probes) or two hours (18
S probe). The membranes were stripped with 5 mvi Tris-HC1, 0.2
M EDTA, 0.5% sodium pyrophosphate, and 5 X Denhardt's
solution for three hours at 70°C. Blots were subsequently rehy-
bridized with the labeled cDNA for the 18 S RNA band to account
for small loading and transfer variations. Exposed films were
scanned as described above, and relative RNA levels were calcu-
lated assigning the hybridizations signal in control lanes a relative
value of one. All Northern blots were independently repeated
three times (separate stimulation and RNA isolation) with qual-
itatively similar results.
Transient transfections and reporter gene assays
The chimeric gene constructs used for transfections were
generously provided by Drs. Geiser, Roberts, and Sporn (National
Cancer Institute, Bethesda, MD, USA) [261, and were A406 (406
bp 5' proximal from the first transcription start site of the murine
TGF-131 gene), B270 (270 bp 5' proximal from the second
transcription start site which is 290 bp distal from the first site, and
AB406 (spanning the region from —406 to the second transcrip-
tion start site). All promoter sequences were coupled to the
CAT-gene [26]. In additional experiments, pA0CAT containing
only the CAT gene and pSV2CAT containing the CAT gene
linked to the SV 40 promoter/enhancer were used as controls.
A total of 5 X i0 MCT, pSV2, and pSV2mas cells were plated
into T-25 culture flasks and grown for 24 hours in DMEM with
10% FCS. Before transfections, cells were extensively washed with
serum-free DMEM to remove any FCS traces. Cells were co-
transfected with 10 xg of each reporter gene construct and the
same amount of the plasmid pSVp-galactosidase in which the SV
40 early promoter and enhancer drives transcription of the lacZ
gene [27]. This plasmid was used for measuring transfection
efficiencies [28]. After 12 hours, the medium was changed to fresh
DMEM without serum and cells were stimulated for an additional
24 hours with a single dose of 108 M Ang II. At the end of the
experiment, cells were washed three times in PBS, and were
subsequently lysed in 100 pd lysis buffer (Reporter Lysis Buffer;
Promega, Madison, WI, USA). After centrifugation, 10 xl of
lysate was used for chemiluminiscent detection of -galactosidase
enzyme activity in a LB 9501 luminometer (Berthold, Wildbad,
Germany) using the Galacto-Ligh(' assay (Tropix, Bedford, MA,
USA). The /3-galactosidase activity was used to normalize the
amount of supernatant used for the CAT-assay [27, 28]. All
volumes were adjusted to 100 uI with 0.25 M Tris-HC1, pH 7.8, and
were heated for 10 minutes at 60°C to inactivate any endogenous
acetylases. For the CAT-assay, 25 pd heat-inactivated lysate, 5 xl
4 mi acetyl coenzyme A, 1 jxl 14[C]chloramphenicol (40 to 60
Ci/mmol, New England Nuclear, Dreieich, Germany), and 18 jxl
distilled water were mixed and incubated for one hour at 37°C.
['4C]chloramphenicol products were extracted in ethyl acetate,
dried under vacuum, and resuspended in 20 u' ethyl acetate [28].
A spot of 5 d of each sample was applied on a silica thin layer
plate and run in chloroform-methanol (95:5, vol:vol). Plates were
dried, sprayed with Enhance°° (New England Nuclear), autora-
diographed for five days at —70°C, and appropriate bands were
cut out and counted for radioactivity ([14C]channel). CAT-assays
were repeated three times.
In addition to CAT-assays, luciferase reporter assays were
performed with selected plasmids [29]. Therefore, enhancer/
promoter elements from the plasmid AB406-CAT (containing
elements from —406 to 310) were subcloned into the pGL2basic
vector. Correct orientation of the insert was confirmed by restric-
tion analysis and partial sequencing. Cells were co-transfected and
stimulated as described above. pGL2 control in which the lucif-
erase gene is activated by SV 40 enhancer/promoter sequences
served as positive control in these experiments [291. Luciferase
activity was measured in 50 pd lysate using Promega's luciferase
assay system. A ratio between luciferase activity and /3-galactosi-
dase activity was calculated and activities in cells treated with
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Control 10-8 M Ang II 10-8 M Ang II
+ anti-TGF-13 Ab
Fig. 1. Bioassay for TGF-p using mink lung epithelial cells (CCL-64 cells).
Symbols in A are: () pSV2; () c-mas. In B symbols are: () pSV2; ()
MCT. Quiescent CCL-64 cells were incubated with conditioned superna-
tants without prior activation. (A) Supernatants obtained from pSV2 cells
treated with a single dose (10 to l0 M) of Ang 11 for 24 hours
significantly inhibited [3H]thymidine incorporation into CCL-64 cells.
However, MCT cells transfccted with c-mas failed to release growth
inhibitory substances for CCL-64 cells into culture supernatant subse-
quent to Ang II treatment (Absolute counts were 2.9 0.70 for pSV2
control, and 2.7 0.31 X iO' CPM for c-mas control). (B) The growth
inhibitory activity for CCL-64 cells in conditioned culture supernatants
obtained from MCT cells and MCT cells transfected with pSV2 subse-
quent to Aug II stimulation was abolished by 30 jsg/ml of neutralizing
anti-TGF- monoclonal antibody (anti-TGF-p Ab), indicating that the
antimitogenic substance is TGF-. N = 12, P < 0.01 vs. control.
control medium (no Ang II) were assigned a value of one.
Transfections, stimulations, and luciferase assays were repeated
four times.
Statistical analysis
All data are presented as a mean SEM. Statistical significance
between more than two groups was first tested with the nonpara-
metric Kruskal-Wallis test for multiple comparisons. If this test
was significant, individual groups were tested using the Wilcoxon-
Mann-Whitney-test. A P value of < 0.05 was considered signifi-
cant.
0
Fig. 2. Sandwich ELISA for TGF-p1 in culture supernatants from (LI)
MCT, (El) pSV2, and (R) c-mas transfected cells. Culture supernatant was
acid activated prior to ELISA to determine total TGF-1. Ang II in a dose
of 10-8 to 10' M for 24 hours significantly stimulated synthesis and/or
release of TGF-f31 in culture supernatants form MCT and pSV2 cells, but
not from MCT cells permanently transfected with c-mas. N = 12, p <
0.01 vs. controls.
Results
TGF-/3 protein expression
We first studied whether the induction of bioactive TGF-13 was
different in the three cell lines used. CCL-64 mink lung epithelial
are growth inhibited in the presence of bioactive TGF-f3 making
this cell line a sensitive bioindicator for the presence of the
cytokine [20]. As shown in Figure 1 (upper panel), conditioned
supernatant from pSV2 cells treated for 24 hours with a single
dose of i0- to 10 6 M Ang II significantly inhibited the prolif-
eration of CCL-64 cells in serum-free medium. Direct incubation
of CCL-64 with 106 M Ang II had no significant influence on
[3H]thymidine incorporation (101 5% of controls, not signifi-
cant vs. controls, N = 6). However, conditioned culture superna-
tants obtained from pSV2mas cells treated with the same concen-
trations of Ang II revealed no release of growth inhibitory
substances for CCL-64 cells. In a second set of experiments, the
wild-type MCT cells as well as pSV2 cells were treated with 10-8
M Ang II, and CCL-64 cells were incubated with their conditioned
supernatants in the absence and presence of 30 g/ml of a
neutralizing anti-TGF-j3 antibody [21]. Conditioned supernatants
from MCT and pSV2 cells treated with Ang II inhibited the
proliferation of CCL64 (Fig. I B). However, the presence of the
neutralizing anti-TGF-1 to 3 antibody abolished this inhibition of
proliferation. Incubation of CCL-64 with anti-TGF-/31 anti-
body and control supernatants (no Ang II) obtained from MCT
and pSV2 cells revealed no effect on mitogenesis of the mink
epithelial cells (data not shown). These experiments indicate that
Ang 11-treatment of MCT and pSV2 cells, but not pSV2mas cells,
stimulates the release of bioactive TGF-p into the culture me-
dium.
We next confirmed these findings of the bioassay with a
sensitive sandwich-ELISA for TGF-f31. For these experiments,
supernatants from MCT, pSV2 and pSV2mas cells were acid
treated to convert latent into active TGF-f31. Therefore, this assay
measured total and not only bioactive TGF-131. As demonstrated
in Figure 2, 10 It) to 10' M Ang II for 24 hours significantly
stimulated release of total TGF-f31 into culture supernatants of
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Fig. 3. (A) Semiquantitative cDNA amplification
for TGF-/3,. cDNA amplifications were peiformed
after reverse transcription of total RNA as
described in the Methods section. Fifteen
microliters of each reaction product were
separated in a 1.9% agarose gel. The correct
identity of the amplification products of
predicted size was confirmed by hybridization to
specific internal primers. A single dose of 108
M Ang II for 24 hours significantly stimulated
increase in TGF-J3 transcripts in pSV,, but not
in pSV2mas cells (pSV2 cells: controls 1.00
0.12, Ang II for 24 hr 2.82 0.25*, Ang II for
48 hr 3.20 0.30*; pSV2mas cells: controls 1.00
0.18, Ang II for 24 hr 0.82 0.07, Ang II for
48 hr 0.60 0.40; relative changes in
amplification product; *P < 0.01 vs. controls, N
= 4 independent stimulation, transcription, and
eDNA amplification reactions). c-mas
transcripts were detected in c-mas transfected
MCT cells, but not in the pSV2 cell line. This
gel is representative of N = 4 independent
stimulation, transcription, and eDNA
amplifications. (B) To better estimate the
correct quantity of amplification products
independently from cycle number, competitive
eDNA amplification with an internal standard
with the same primer binding sides was used.
Amplified TGF-13 target cDNA (RT-cDNA)
and internal standard are separated by gel
electrophoresis because of different sizes (size
of RT-cDNA 471 bp, size of internal standard
390 bp). A ratio between target eDNA and
internal standard was calculated. Ang II for 24
hours significantly stimulated expression of
TGF-f3 transcripts in pSV2 cells, but not in the
pSV2mas cell line (pSV2 cells: control 1.00
0.20, 10 M Ang 111.74 0.31", iO M Ang
111.38 0.28'; pSV2mas: control 1.00 0.18,
10 M Ang II 0.74 0.24, iO M Ang II 0.63
0.15*; relative changes in amplification
product normalized to internal standard; 'P <
0.05 vs. controls, N = 4).
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MCT and pSV2 cells. In contrast, Ang II had no significant effect
on TGF-/31 in pSV2mas cells.
TGF-/31 mRNA expression
cDNA amplification of reversed transcribed mRNA was used as
an initial method to quantify Ang IT-induced TGF-/31 expression
in pSV2 and pSV2mas cells. We have previously, in a series of
studies, demonstrated the reliability of this method and have
standardized the parameters [23, 241. Moreover, we have previ-
ously shown that 108 M Ang II stimulated the expression of
TGF-/31 transcripts in MCT cells as measured by eDNA amplifi-
cation [101. Although 10 M Ang II significantly stimulated
TGF-p, transcripts in pSV2 cells, the peptide inhibited TGF-131
expression in the cell line transfected with c-mas (Fig. 3A; pSV2
cells: controls 1.00 0.12, Ang II for 24 hr 2.82 0.25", Ang II
for 48 hr 3.20 0.30; pSV2mas cells: controls 1.00 0.18, Ang
II for 24 hr 0.82 0.07, Ang II for 48 hr 0.60 0.40; relative
changes in amplification product normalized to GAPDH; 'P <
0.01 vs. controls, N = 4 independent stimulation, transcription,
and cDNA amplification reactions). Furthermore, eDNA ampli-
fication of c-mas revealed, as predicted, that pSV2 cells do not
express mRNA for this oncogene, and the expression of c-mas
transcripts does not change after Ang IT-stimulation in the
pSV2mas cell line (Fig. 3A). To more accurately determine the
level of TGF- transcripts, we also performed amplification
reactions with an internal standard of known concentrations
exhibiting the same primer templates as the target, thus compet-
ing with target cDNA for the same primer. Amplified TGF-13
target eDNA and internal standard are separated by gel electro-
phoresis because of different sizes. A ratio between target cDNA
and internal standard was calculated. As shown in Figure 3B, 1O7
to 10_6 M Ang II for 24 hours significantly stimulated expression
of TGF-p transcripts in pSV2 cells, but not in the pSV2mas cell
line (pSV2 cells: control 1.00 0.20, 10_6 M Ang 111.74 0.31*,
iO M Ang 111.38 0.28; pSV2mas: control 1.00 0.18, 10_6
M Arig II 0.74 0.24, i0 M Ang II 0.63 0.15*; relative changes
in amplification product normalized to internal standard; *p <
0.05 vs. controls, N = 4).
To validate the findings from the cDNA amplifications, North-
ern blots were performed. A single dose of 108 M Ang II for 12
and 24 hours stimulated TGF-f3, mRNA expression in pSV2, but
not in pSV2mas cells (Fig. 4; pSV2 cells: controls 1.00, 12 hr Ang
II 2.11, 24 hr Ang II 7.70; pSV2mas: controls 1.00, 12 hr Ang II
0.59, 24 hr Ang II 1.34; changes in relative mRNA levels).
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Fig. 4. Northern blot of 20 p.g total RNA
isolated from pSV2 and pSV2mas cells after
stimulation for 12 and 24 hours with a single
dose of 10 M Ang II. The vasoactive peptide
stimulated TGF-1 transcripts after 12 hours,
with a greater effect at 24 hours. In contrast,
Ang 11 did not significantly stimulate TGF-31
mRNA expression in pSV2mas cells (c-mas).
The blots were rehybridized with a probe
encoding the ribosomal 18 S band to account
for small variations in loading and transfer of
total RNA (pSV2 cells: controls 1.00, 12 hr Ang
II 2.11, 24 hr Ang II 7.70; pSV2mas: controls
1.00, 12 hr Ang II 0.59, 24 hr Ang 111.34;
changes in relative mRNA levels). This blot is
representative of three independent
experiments with qualitatively similar changes.
Fig. 5. Dose-response curves reveals that a
single dose of 10 and 10 M Ang II for 24
hours stimulated TGF-[3, mRNA in parental
MCT and pSV but not in pSV2mas cells (c-
mos). A ratio between the hybridization
signals for TGF-p1 and 18 S was calculated
to account for variations in total RNA
loading and transfer (MCT cells: controls
1.00, t0' M Ang 111.20, iO M Ang 11
2.63; pSV2 cells: controls 1.00, 10"' M Ang
111.80, i0- M Ang 11 4.23; pSV2mas:
controls 1.00, 10"' M Ang 11 0.63, 10"' M
Aug II 0.87; changes in relative mRNA
levels). This blot is representative of three
independent experiments with qualitatively
similar changes.
Dose-response curves revealed that i0"' and i0 M Ang II for 24 1O8 M Ang II 4.23; pSV2mas: controls 1.00, 10_6 M Ang II 0.63,
hours induced TGF-/31 transcript expression in MCT and pSV2 iO M Aug II 0.87; changes in relative mRNA levels).
cell lines. However, treatment of pSV2mas cells with the same
concentrations of Aug II failed to stimulate TGF-f31 mRNA Transient expression studies
expression (Fig. 5; MCT cells: controls 1.00, 106 M Ang 111.20, To determine whether the absence of Ang 11-mediated induc-
iO M Ang II 2.63; pSV2 cells: controls 1.00, 10"" M Aug 111.80, tion of TGF-f31 in the pSV2mas cell line might be due to failure of
Fig. 6. Representative autoradiograms of thin
layer chromatography plates after separation of
ace/ylated '4[CJchloramphenicol (CAT activity)
from unacelylated forms. An increase in
acetylated products reflects stimulation of gene
transcription. 10 M Ang II stimulated
transcription of TGF-1 promoter constructs
A406 and B270 in MCT and pSV2 cells, but
had only very little activity in pSV2mas cells
(c-mas). This experiment was performed three
times (separate transient transfections,
stimulation, CAT assay and thin layer
chromatography) with similar results.
stimulation of TGF-p1, chimeric reporter gene constructs contain-
ing murine TGF-p1 promoter/enhancer elements were transiently
transfected in MCT, pSV,, and pSV2rnas cells. The murine
TGF-p gene exhibits two transcriptional start sites separated by
a sequence of 290 base pairs. Two reporter gene constructs
containing regulatory elements of the first (A406) and the second
(B270) TGF-pI transcriptional start site linked to the CAT gene
were used for transient transfection studies [261. As shown in
Figure 6, Ang 11 stimulates transcriptional activation of both
reporter gene constructs in MCT and pSV2 cells. Transcriptional
activation of enhancer/promoter elements obtained from the first
transcriptional start site was somewhat stronger in pSV2 cells
compared with the parental MCT cell line (MCT cells: pA0 1.00,
pSV2 4.01, A406 + control medium 1.00, A406 + Ang II 8.41,
B270 + control medium 1.00, B270 + Ang II 7.68; pSV2 cells: pA0
1.00, pSV2 5.38, A406 + control medium 1.00, A406 + Ang IT
4.52, B270 + control medium 1.00, B270 + Ang II 6.66; relative
CAT activity, mean of three independent experiments). However,
Ang TI-induced transcriptional activation of both constructs was
severely attenuated in pSV,mas cells (Fig. 6; pSV7mas cells: A406
+ control medium 1.00, A406 + Ang II 1.40, B270 + control
medium 1.00, B270 + Ang 111.29; relative CAT activity, mean of
three independent experiments). Co-transfections with a plasmid
encoding -ga1actosidase revealed equal transfection efficiencies
in the three cell lines (data not shown). Similar results were
obtained when the concentration of lysates used for the CAT
assays was normalized for total protein concentrations instead of
-galactosidase activity (data not shown).
In addition to CAT assays, more sensitive luciferase reporter
Controls io- M Ang TT
MCT cells 1.00 0.01 1.67 0.25a
pSV2 cells 1.00 0.08 2.34 0.78a
pSV, mas 0.98 0.03 0.94 0.07
Relative luciferase activities normalized to 13-galactosidase. N = 4
independent transfection and stimulation experiments.
P < 0.01 versus controls
plasmids were used in selected experiments [29]. For this reason,
enhancer/promoter sequences from the CAT construct AB406
which contains regulatory elements from both transcriptional start
sites were subcloned in front of the luciferase gene. Cells were
co-transfected with this construct along with a /3-galactosidase
expression plasmid, and luciferase activities normalized to a-ga-
lactosidase were measured 24 hours after Ang TI stimulation.
Table I reveals that luciferase activity of AB406 is significantly
stimulated after Ang TI treatment in MCT and pSV2, but not in
pSV2mas cells. This difference is not due to changes in transfec-
lion efficiencies in the various cell lines since luciferase activities
of the control plasmids pGL2 basic (only luciferase gene) and
pGL2 (luciferase gene under control of SV 40 enhancer/pro-
moter) were comparable in all three cell lines (MCT cells: pGL2
basic 0.89 0.06, pGL2 control 15.04 1.74*; pSV2 cells: pGL2
basic 0.99 0.06, pGL2 control 14.12 1.52*; pSV2mas: pGL2 basic
1824 Wolfet al: TGF-p expression and c-mas
Table 1. Relative luciferase activities of the reporter construct AB406
in the various cell lines after stimulation with Ang II
MCT cells
A406+ Icontrol medium
pSV2
A 406 +
control medium
B 270 +
control medium
B 270 +
Ang Il
A 406 +
Ang II
pA0
pSV2
A 406 +
control medium
B 270 +
control medium
B 270 +
Ang II
A 406 +
Ang II
pA0
pSV2
A 406 +
Angll I
c-mas
B 270 +
Control medium S
B 270 +
Ang Il I
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0.88 0.04, pGL2 control 15.09 1.93*; relative luciferase
activities, N = 4 to 6, *D < 0.001 vs. pGL2 basic).
Discussion
Since the original studies in vascular smooth muscle cell [30],
evidence has been accumulating that Ang II can act as a growth
factor. Since initial compensatory renal growth processes includ-
ing glomerular and tubular hypertrophy are important in the
maladaptive responses leading to irreversible structural changes
and the progression of renal disease [31], several investigators
have focused on Ang II as a potential renal growth factor [8, 9,
32—34]. Seminal studies by Brenner and colleagues more than a
decade ago have clearly established the importance of changes in
glomerular hemodynamics in the pathogenesis of chronic renal
failure [351. Since Ang II is partly responsible for these hemody-
namic changes [36], the vasoactive peptide may provide a link
between hemodynamic changes, adaptation in tubular transport,
and compensatory renal growth, all playing pivotal roles in the
progression of renal disease [311. Although there is evidence that
angiotensin converting enzyme inhibitor as well as Ang II receptor
blocker attenuate renal growth in various animal models [37, 381
and that targeted overexpression of renin and angiotensinogen in
mesangial cells leads to glomerular growth effects in vivo [39], the
majority of observations identifying Ang II as a growth factor stem
from in vitro experiments in which Ang II may be studied as a
single factor in a defined environment without additional inter-
ference by hemodynamic and metabolic factors [6—9].
We and others have previously shown that Ang II, as a single
factor, stimulates cellular hypertrophy in cultured proximal tubu-
lar cells from different species [6—9]. This hypertrophy is due to an
increase in protein synthesis and an inhibition in protein catabo-
lism in the absence of DNA replication. In fact, mitogenesis is
inhibited in cultured proximal tubular cells treated with Ang II [6,
7]. We have also previously shown that the Ang TI-induced
hypertrophy of MCT cells depends on the endogenous synthesis
of TGF-p and can be abolished in the presence of a neutralizing
anti-TGF-j3 antibody [10]. Moreover, exogenous TGF-f31 inhibits
G1-S-transition of proximal tubular cells and induces cellular
hypertrophy [401.
Until the cloning of the AT1 -receptor for Ang II independently
by two groups in 1991, it had been suggested that the protein
product of the c-mas oncogene acted as a receptor for Ang II [15,
411. This assumption stems from c-mas overexpression studies in
COS and neuronal cells, as well as in Xenopus oocytes in which
Ang II induces physiological responses and activation of second
messengers systems in c-mas expression, but not control cells [13,
14, 42]. Moreover, the c-mas oncogene also encodes a member of
a superfamily of receptor-like moieties with seven transmembrane
spanning regions that couple to G proteins [11, 43]. Our original
objective, when we started these studies several years ago, was to
overexpress c-mas as a potential Ang II receptor in MCT cells and
to examine whether overexpression of Ang II receptors further
enhances the hypertrophy induced by the vasoactive peptide [17].
However, surprisingly we learned that permanent transfection of
MCT cells with the c-mas oncogene under the control of SV 40
enhancer/promoter elements changed the hypertrophogenic effect
of Ang II into a proliferative response [17]. This effect was not due
to the transfection and G418 selection process, since MCT cells
permanently transfected with the SV 40-based expression vector
pSV2 without c-mas insert behaved like wild-type MCT cells, and
these cells showed no signs of proliferation subsequent to Ang II
stimulation [17]. In addition, the proliferative response to Ang II
in pSV2mas cells was not due to changes in surface receptor
expression, since binding kinetics of Ang II receptor were similar
in MCT, pSV2, and pSV2mas cells. Interestingly, in pSV2mas
transfected cells the signal transduction was shifted from inhibi-
tion of adenylate cyclase (as demonstrated in MCT cells) to
activation of inositol phosphate-diacylglycerol-protein kinase C
pathway which is normally not activated by Ang II in MCT cells
[17].
The present study was undertaken to test the hypothesis that
Ang II fails to activate TGF-131 in MCT cells transfected with the
c-mas oncogene. Such a disruption of Ang IT-mediated TGF-/31
induction may explain why the vasopeptide is mitogenic for
pSV2mas cells since the G1-S phase arrest induced by TGF-p1 is
abolished. Our results clearly demonstrate that TGF-p1 protein
synthesis, mRNA expression and transcription is partly abolished
in pSV2mas cells stimulated with Ang II. This abrogated response
is not due to the transfection process per se or due to the
expression of SV 40 enhancer/promoter elements since MCT cells
transfected with pSV2 alone exhibited Ang Il-mediated induction
of TGF-p1. The murine as well as human TGF-p1 promoter have
been recently characterized: they contain two transcriptional start
sites and there is an absence of TATA or CAAT box sequences,
but several Spi-binding and AP2-Iike sequences are present [26,
44]. Furthermore, sequences resembling phorbol ester response
elements which are recognized by proteins from the AP-1 family
of transcription factors are present upstream of TGF-131 gene [45].
Although we have not formally investigated potential bindings
sites in the murine TGF-/31 promoter for Ang IT-induced nuclear
trans-acting factors, the transfection studies using different chi-
meric gene constructs clearly demonstrate in MCT and pSV2 cells
that Ang II stimulates TGF-f31 gene transcription from both
promoters. Since Ang IT induces c-fos [6] and c-jun (unpublished
observations) in MCT cells, and the protein products of these two
immediate early genes form a leucine zipper which can bind to
AP-1 sites [461, it is possible that the Ang TI-stimulated transcrip-
tion of TGF-/31 is mediated through this AP-1 site. Further
experiments like gel mobility shift assays applying selected pro-
moter sequences are necessary to correctly identify putative
binding elements for Ang lI-induced trans-acting factors in the
murine TGF-p1 promoter.
The Ang LI-mediated transcriptional activation of both murine
TGF-/31 promoters was partly abolished in pSV2mas cells. AT1-
receptors in proximal tubular cells have a complex combination of
signal transduction pathways [47, 48]. After binding of the pep-
tide, adenylate cyclase is inhibited resulting in a decrement of
intracellular cAMP. Furthermore, activation of phospholipase A2
and calcium channels has been described [49]. The Ang II-
activated calcium channels are dihydropyridine-sensitive and are
activated by 5,6-epoxyeicosatrienoic acid (5,6 EET) which is
generated from arachidonic acid by cytochrome P450 epoxygen-
ase [49]. Tn addition, Ang IL-induced activation of phospholipase
C with subsequent formation of inositol 1,4,5-trisphosphate (IP3)
has been described in proximal tubular cells [50]. Since we have
previously demonstrated that Ang II stimulated intracellular
accumulation of 1P3 in pSV2mas cells [17], it is possible that this
signal transduction pathway plays a role in the different induction
of TGF-13. It remains to be studied at which level the Ang II signal
transduction cascade is attenuated in c-mas transfected MCT
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cells. However, our original experiments indicated that overall
expression of membrane Ang II receptors is not different in MCT
and pSV2mas cells, suggesting that the alteration of signal trans-
duction in c-mas transfected MCT cells is distal to the Ang
lI-receptor [17].
Activation of the c-mas oncogene in tumorigenicity assays has
been described for DNA isolated from epidermoid carcinoma,
ovarian carcinoma and acute leukemia [11, 12, 51]. A rearrange-
ment in the 5' non-coding with an intact c-mas coding sequence
was found in these cases of different human neoplasms, indicating
transcriptional overexpression of c-mas [12, 51]. In addition,
injection of nude mice with up-regulated c-mas resulted in the
development of tumors [51]. Since TGF-131 is a well-known
inhibitor of proliferation for many tissues, and disturbance as well
as escape from TGF-f31-mediated normal growth control have
been described in a variety of tumors [52, 53], it is tempting to
speculate that TGF-131 induction is altered in tumors overexpres-
sion c-mas, thus leading to uncontrolled proliferation of cells.
Since intrarenal concentrations of Ang II are elevated in many
pathophysiological situations [54], Ang Il-mediated induction of
TGF-131 in proximal tubular cells may have several disastrous
effects on the kidney. TGF-131 is a well-known stimulator of
transcription and synthesis of various collagens [551. Moreover, it
inhibits collagen degradation leading to structural changes of
glomerulosclerosis and tubulointerstitial fibrosis [55]. It has been
demonstrated in several models of immune and non-immune
chronic renal disease that neutralization of TGF-3 maintains
renal function and prevents development of renal fibrosis [40, 55,
56]. Therefore, it is an important task to elucidate how Ang II
induces TGF-131 transcription and synthesis in renal cells, and how
such an induction can be prevented. The c-mas transformed cell
line in which Ang II fails to stimulate TGF-j31 transcription may
be a promising tool to further study the complex relationship
between cell membrane binding of the vasoactive factor and
nuclear transcription of a cytokine like TGF-f31.
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